NCT03645421 - Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2018

Primary Completion Date

January 17, 2019

Study Completion Date

January 17, 2019

Conditions

Type 2 Diabetes

Interventions

DRUG

MEDI0382 100 μg

Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose

DRUG

MEDI0382 200 μg

Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose

DRUG

MEDI0382 300 μg

Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose

DRUG

PlaceboA

1.0 mL liquid formulation per Vial

DRUG

MEDI0382 50 ug

Solution for injection, 1.0 mL per vial, 50 ug

DRUG

PlaceboB

Solution for injection in 1.0 mL pre-filled syringe.

Trial Locations (5)

Research Site, Chūōku

Research Site, Chūōku

Research Site, Shinjuku-ku

Research Site, Shinjuku-ku

Research Site, Suita-shi